March 2021

Subject: Tecentriq® (atezolizumab) indication in prior-platinum locally advanced or metastatic bladder cancer is being voluntarily withdrawn in the U.S.

Dear Health Care Provider:

This letter is to inform you about an important change to the Tecentriq (atezolizumab) label for the treatment of prior-platinum locally advanced or metastatic bladder cancer.

Indications

Genentech, a member of the Roche Group, announced on Monday March 8, 2021 that they are voluntarily withdrawing the U.S. indication for Tecentriq for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in patients whose disease has progressed during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA) as part of an industry-wide review of accelerated approvals with confirmatory trials that did not meet their primary endpoint(s) and have yet to attain regular approval.

This change does NOT impact other approved Tecentriq indications in the US, including for patients with cisplatin-ineligible mUC whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area) or for patients with mUC who are ineligible for any platinum-containing chemotherapy, regardless of PD-L1 status.

Prescriber Action

A Dear Patient Letter is enclosed. Please share this letter with your patients who are currently receiving Tecentriq for the treatment of prior-platinum advanced bladder cancer and discuss the impact of the withdrawal of this indication on their treatment plans.
Reporting Adverse Events

Health care providers and patients are encouraged to report adverse events or side effects related to the use of these products to Genentech at 1-888-835-2555.

Alternatively, this information may be reported to FDA’s MedWatch reporting system by phone (1-800-FDA-1088) or online (www.fda.gov/medwatch).

Company Contact Point

You may also contact the Genentech Medical Communications department at 1-800-821-8590 if you have any questions about the information contained in this letter or the safe and effective use of Tecentriq.

This letter is not intended as a complete description of the benefits and risks related to the use of Tecentriq. Please refer to the enclosed full prescribing information and medication guide. The revised Tecentriq prescribing information is not yet available, but you will receive a follow-up letter with the updated full prescribing information as soon as it is available.

Sincerely,

Jamie Freedman MD, PhD
Head of U.S. Medical Affairs